RMC No. 112-2022 updates the VAT-exempt medicines list under the CREATE Act, adding tuberculosis medicines and removing COVID-19 medicines, affecting tax compliance for healthcare providers.

Businesses in the pharmaceutical and healthcare sectors must immediately update their records and compliance processes due to the newly endorsed changes to the VAT-exempt medicines list. Certain medicines prescribed for tuberculosis are now officially exempt from value-added tax (VAT), while medicines used for COVID-19 treatment have been removed from the exemption list. This change directly affects sales, invoicing, and tax reporting for healthcare providers, pharmacies, and distributors.

What Changed

RMC No. 112-2022 publishes the June 27, 2022 letter from the Food and Drug Administration (FDA) OIC-Director General Oscar G. Gutierrez, Jr., updating the list of medicines exempt from VAT under Republic Act No. 11534 (CREATE Act). Notably, medicines for tuberculosis treatment have been added, while COVID-19 medicines are no longer exempt. This clarifies which medical products qualify for VAT exemption, aligning BIR enforcement with current FDA guidance.

Who is Affected

Pharmaceutical manufacturers, wholesalers, distributors, retail pharmacies, and hospitals that sell or supply the listed medicines are directly impacted. Accounting and tax compliance teams in these organizations must adjust their VAT reporting and ensure that sales invoices for newly exempt medicines do not include VAT. Conversely, entities handling COVID-19 medicines must now account for VAT on sales previously considered exempt.

Key Compliance Requirements and Deadlines

According to the RMC and the guidance under Q&A No. 1 of RMC No. 99-2021, the VAT exemption for the covered medicines takes effect on the date of publication by the FDA of the updates to the list. Businesses must:

1. Update accounting systems and sales processes to reflect the new VAT treatment immediately.

2. Train sales and billing staff to apply VAT correctly on affected medicines.

3. Maintain proper documentation for VAT-exempt sales of newly covered medicines to ensure compliance in case of audit.

4. Remove VAT exemption treatment for COVID-19 medicines in billing, invoicing, and tax filings.

Penalties for Non-Compliance

Failure to apply VAT correctly may result in assessments, penalties, and interest as prescribed under the National Internal Revenue Code. Businesses must ensure their tax filings reflect the updated exemptions to avoid exposure to additional tax liabilities and administrative sanctions.

Practical Steps for Businesses

1. Review the FDAโ€™s updated list of VAT-exempt medicines.

2. Coordinate with tax advisors and internal accounting teams to implement system and procedural updates.

3. Communicate changes to pharmacy and hospital billing departments to prevent incorrect VAT treatment.

4. Keep records of updated VAT-exempt sales and related documentation for future audits.

By taking these steps, businesses can ensure compliance with RMC No. 112-2022 and the CREATE Act, minimizing risk and aligning operations with the latest FDA-endorsed VAT rules.

About Ablola, Saribong & Gueco

For Philippine businesses navigating VAT exemptions and other regulatory updates, Ablola, Saribong & Gueco provides authoritative guidance and practical solutions. Our team helps ensure compliance with the latest BIR issuances and FDA directives. Visit MakatiLawFirm.com to connect with our tax and corporate law experts for tailored support.


Leave a Comment

Your email address will not be published. Required fields are marked *